Shailender Bhatia
Fred Hutch/University of Washington Cancer Consortium · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shailender Bhatia as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07576725 · Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialFred Hutchinson Cancer Center · not yet recruiting · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 · principal investigator
- Ph2NCT06056895 · Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell CarcinomaUniversity of Washington · active not recruiting · Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma · principal investigator
- Ph3NCT03271372 · Adjuvant Avelumab in Merkel Cell CancerUniversity of Washington · active not recruiting · Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8 · principal investigator
- Ph2NCT01440816 · IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell CancerOncoSec Medical Incorporated · completed · Merkel Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026Named on NCT01440816
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:57 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med · 20126,565 citationsRCR 174.5
- O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.Cancer Cell · 2017324 citationsRCR 11.3
- 245 citationsRCR 50.5
- 119 citationsRCR 4.0
- 82 citationsRCR 19.0
- A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.Lung Cancer · 200233 citationsRCR 0.9
- Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.Clin Lung Cancer · 201312 citationsRCR 0.3
- 7 citationsRCR 0.2